Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

John Lutz

Interventional Pain Medicine Jackson, MS Medical Doctor

NPI 1255628020 CMS profile 769686

1325 E Fortification St, Jackson, MS 39202

Open in the dashboard

General payments

$4,542

103 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Lutz of Jackson, MS is reported in the CMS Open Payments database as having received $4,542 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $466 32
2024 General $349 17
2023 General $1,615 24
2022 General $2,032 24
2020 General $81 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Lutz
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to John Lutz were reported at $466. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year John Lutz Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $81 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $2,032 $605 $187–$1,924 $149
2023 $1,615 $671 $195–$1,915 $160
2024 $349 $684 $206–$1,837 $164
2025 $466 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Boston Scientific Corporation $3,111 80 payments
  2. Abbott Laboratories $661 6 payments
  3. Medtronic, Inc. $399 5 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $136 1 payment
  5. SPR Therapeutics, Inc $68 2 payments
  6. Nalu Medical, Inc. $61 3 payments
  7. Avanos Medical $34 2 payments
  8. Stryker Corporation $22 1 payment
  9. SI-BONE, Inc. $21 1 payment
  10. GRT US Holding, Inc. $15 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,715 99 payments
  2. Travel and Lodging $828 4 payments
Products named General payments · program years 2020–2025
  1. WaveWriter Alpha Prime 16 $873 24 payments
  2. PROCLAIM $661 6 payments
  3. Superion Indirect Decompression System $453 5 payments
  4. General - Pain Management General - Pain Management_NMD $402 14 payments
  5. INTELLIS ADAPTIVESTIM $379 4 payments
  6. GENERAL - PAIN MANAGEMENT Pain Management $149 3 payments
  7. RELISTOR $136 1 payment
  8. Intracept $94 1 payment
  9. SPRINT PNS System $68 2 payments
  10. Nalu Neurostimulation System $61 3 payments
  11. Other $195 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

2,043

Median for Pain Management: 951

Drug cost

$20,086

Median for Pain Management: $26,034

Branded share of claims

10.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 191 $5,340
Gabapentin Generic 353 $2,848
Diclofenac Sodium Generic 252 $2,659
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 152 $2,305
Methocarbamol Generic 240 $1,983
Tramadol Hcl Generic 197 $1,031
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 32 $864
Meloxicam Generic 312 $790
Cyclobenzaprine Hcl Generic 111 $767
Tizanidine Hcl Generic 61 $559

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$176,577

Of which drugs: $225

Medicare patients

485

Average age 75

Services billed

3,949

302 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 33%
Depression 22%
Chronic kidney disease 19%
Atrial fibrillation 17%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 22 1,680 $170
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 23 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record